Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial

Journal of Medical Imaging and Radiation Oncology

Volumn 57, Issue 2, 2013, Pages 247-257

  Kearvell, Rachel ^a   Haworth, Annette ^d,e   Ebert, Martin A ^a,b   Murray, Judy ⁱ   Hooton, Ben ^a   Richardson, Sharon ^a   Joseph, David J ^a,b   Lamb, David ⁱ   Spry, Nigel A ^a,c   Duchesne, Gillian ^d,f,g   Denham, James W ^h  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e RMIT UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

clinical trial; prostate cancer; quality assurance; radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ARTICLE; AUSTRALIA; CANCER RADIOTHERAPY; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; NEW ZEALAND; PATIENT POSITIONING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RELIABILITY; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; VALIDITY;

AUSTRALIA; GUIDELINES AS TOPIC; HUMANS; MALE; NEW ZEALAND; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 84875851707     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12025     Document Type: Article

References (35)

1. Bydder S, Spry N,. Chemotherapy for pancreatic cancer. N Engl J Med 2004; 350: 2713-2715.
2. Deasy JO, Niemierko A, Herbert D, et al. Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. Med Phys 2002; 29: 2109-2127.
3. Roos DE, Davis SR, Turner SL, et al. Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman Radiation Oncology Group, 96.05). Radiother Oncol 2003; 67: 207-212.
4. Pettersen MN, Aird E, Olsen DR,. Quality assurance of dosimetry and the impact on sample size in randomized clinical trials. Radiother Oncol 2008; 86: 195-199.
5. Peters LJ, O'Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010; 28: 2996-3001.
6. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16(INK4A) and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
7. Ibbott GS, Followill DS, Molineu A, Lowenstein JR, Alvarez PE, Roll JE,. Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys 2008; 71: S71-75.
8. Fairchild A, Aird E, Fenton PA, et al. EORTC Radiation Oncology Group quality assurance platform: establishment of a digital central review facility. Radiother Oncol 2012; 103: 279-286.
9. Steigler A, Mameghan H, Lamb D, et al. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01). Australas Radiol 2000; 44: 65-71.
10. Palta JR, Frouhar VA, Dempsey JF,. Web-based submission, archive, and review of radiotherapy data for clinical quality assurance: a new paradigm. Int J Radiat Oncol Biol Phys 2003; 57: 1427-1436.
11. Purdy JA, Harms WB, Michalski J, Bosch WR,. Initial experience with quality assurance of multi-institutional 3D radiotherapy clinical trials. A brief report. Strahlenther Onkol 1998; 174 (Suppl 2): 40-42.
12. Matzinger O, Poortmans P, Giraud JY, et al. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol 2009; 90: 285-290.
13. Purdy JA,. Quality assurance issues in conducting multi-institutional advanced technology clinical trials. Int J Radiat Oncol Biol Phys 2008; 71: S66-70.
14. TROG. TROG Clinical Trials Summary. TROG 03.04-randomised trial investigating the effect on survival and PSA control of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate (RADAR). TROG; 2005. [Cited 13 July 2012.] Available from URL: http://clinicaltrials.gov/ct/show/NCT00193856?order= 5.
15. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105.
16. Christie D, Denham J, Steigler A, et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 2005; 77: 117-125.
17. Haworth A, Kearvell R, Greer PB, et al. Assuring high quality treatment delivery in clinical trials-results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 'RADAR' set-up accuracy study. Radiother Oncol 2009; 90: 299-306.
18. Ebert MA, Harrison K, Howlett S, et al. Dosimetric intercomparison for multicentre clinical trials using a patient-based anatomic pelvic phantom. Med Phys 2011; 38: 5167-5175.
19. Ebert MA, Harrison K, Cornes D, et al. A comprehensive Australasian multi-centre dosimetric intercomparison-issues, logistics and recommendations. J Med Imaging Radiat Oncol 2008; 86: 200-210.
20. Ebert MA, Howlett SJ, Harrison K, Cornes D, Hamilton CS, Denham JW,. Linear-accelerator X-ray output: a multicentre chamber-based intercomparison study in Australia and New Zealand. Australas Phys Eng Sci Med 2008; 31: 255-266.
21. Harrison K, Ebert MA, Kron T, et al. Design, manufacture and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison. Med Phys 2011; 38: 5330-5337.
22. Skala M, Berry M, Duchesne G, et al. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Australas Radiol 2004; 48: 493-501.
23. Baxter BS, Hitchner LE, Maguire GQ Jr,. A standard format for digital image exchange. Madison WI: AAPM, 1982.
24. NEMA. Digital Imaging and Communications in Medicine (DICOM) Standard. Office of Publications, Washington, DC, 2001.
25. Ebert MA, Blight J, Price S, et al. Multicentre analysis of treatment planning information: technical requirements, possible applications and a proposal. Australas Radiol 2004; 48: 347-352.
26. Ebert MA, Haworth A, Kearvell R, et al. Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system. Radiother Oncol 2008; 86: 200-210.
27. Ebert MA, Haworth A, Kearvell R, et al. Comparison of DVH data from multiple radiotherapy treatment planning systems. Phys Med Biol 2010; 55: N337-346.
28. ICRU. Prescribing, recording and reporting photon beam therapy. Bethesda, MD: International Commission on Radiological Units; 1999. Report No.: Report 62.
29. Weber DC, Tomsej M, Melidis C, Teglas V, Hurkmans CW,. QA makes a trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 2012; 103 (Suppl 1): S187-188.
30. Fiorino C, Reni M, Bolognesi A, Cattaneo GM, Calandrino R,. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol 1998; 47: 285-292.
31. Rasch C, Barillot I, Remeijer P, Touw A, van, Herk M, Lebesque JV,. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57-66.
32. Gulliford SL, Foo K, Morgan RC, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010; 76: 747-754.
33. Gulliford SL, Partridge M, Sydes MR, Andreyev J, Dearnaley DP,. A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity. Radiother Oncol 2010; 94: 241-247.
34. Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperatvie conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 76: 361-368.
35. James H, Beavis A, Budgell G, et al. Guidance for the clinical implementation of intensity modulated radiation therapy, IPEM; 2008. Report No.: 96.